The Clinical Rationale for Immediate Androgen Deprivation Without Estrogen Deprivation

Clinical Prostate Cancer

Volumn 2, Issue 2, 2003, Pages 127-128

  Pitts Jr , W Reid ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE   (United States)

Author keywords

Bicalutamide; Diethylstilbestrol; LHRH; Prostate specific antigen

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN; BICALUTAMIDE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; GONADORELIN DERIVATIVE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ZOLEDRONIC ACID;

ARTICLE; ASTHENIA; BONE METASTASIS; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG COST; GYNECOMASTIA; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; ORCHIECTOMY; OSTEOPOROSIS; PROSTATE CANCER; THROMBOSIS;

EID: 0142085724     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2003.n.021     Document Type: Article

References (14)

1. Scherr DS, Pitts, WR, Jr. The nonsteroidal effects of diethyistilbestrol (DES): the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 2003; In press.
2. Scherr DS, Pitts, WR, Jr, Vaughan ED, Jr. Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 2002; 167:535-538.
3. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urology Research Group. NCI Mongr 1988; 7:165-170.
4. See WA, Wirth MP, McLeod DG, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. J Urol 2002; 168:429-435.
5. Smith MR, Fallon MA, Goode MJ. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003; 61:127-131.
6. Saad F, Gleason DM, Murray R, et al. A randomized placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. 2002; J Natl Cancer Inst 2002; 94:1458-1468.
7. Huggins C, Hodges CV. Studies on prostate cancer: I. The effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 168:9-12.
8. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995; 154:1991-1998.
9. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 157:439-444.
10. Smith DC, Redman DG, Flaherty LE, et al. A Phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer. Urology 1998; 52:257-260.
11. Burns-Cox N, Basketter V, Higgins B, et al. Prospective randomized trial comparing diethylstilbestrol and flutamide in the treatment of hormone relapsed prostate cancer. Int J Urol 2002; 9:431-434.
12. Messing E, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive cancer. N Engl J Med 1999; 341:1781-1788.
13. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347:781-789.
14. Pitts, WR, Jr. Re: Editorial: the Prostate Puzzle. J Urol 1998; 160:1441-1442.